GMAB
NASD Genmab A/S Sponsored ADR$37.80 ↑ +0.43 (+1.15%) Trading Up from the previous close of $37.37
- YTD change
- +22.73%
- vs 20-day SMA
- +6.19%
- vs 200-day SMA
- +26.95%
Price ranges
Price & Performance
+9.17 (+32.52%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 23.0% away from all-time highs of $49.07
- GMAB is up 23% since the beginning of the year
- GMAB is up 16% over the past 12 months
- GMAB is up 16% over the past 1 month
- 1% of all GMAB investors are betting against GMAB
GMAB reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +14.4%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- -1.77%
- vs 8-day SMA
- +3.31%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
